ARCHIVES

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

This article is from The Cancer Letter archive.

Vol. 34 No. 10 | October 28, 2011

Download PDF Visit The Full Archive

Related Articles

Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent

January 8, 1982

NCI Could Fund Some Challenge Grants That Miss NIH Funding, Director Says

June 26, 2009

NCI Initiatives: Two RFAs Planned In New Technologies for Molecular Biology

December 6, 1996

USC Opts for Its own IL-2 Protocol, Shuns NCI Trial

May 8, 1987

Chemopreventive Phase I, Preclinical Studies Concept Approved

May 13, 1983

In Brief: ACS Awards Professorship To Bernstein; HCFA Clears Dana-Farber For Medicare

August 11, 1995